Ibnsina Pharma (EGX:ISPH)
Egypt · Delayed Price · Currency is EGP 12.08
+0.38 (3.25%)
At close: Oct 4, 2026
Ibnsina Pharma Ratios and Metrics
Market cap in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 12,177 | 11,814 | 7,056 | 3,165 | 2,419 | 3,907 | |
Market Cap Growth | 5.04% | 67.43% | 122.93% | 30.83% | -38.08% | -20.04% |
Enterprise Value | 38,796 | 35,439 | 23,168 | 15,142 | 11,020 | 10,960 |
Last Close Price | 12.08 | 11.58 | 6.82 | 3.06 | 2.11 | 3.20 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 13.99 | 15.32 | 14.17 | 18.28 | 17.84 | 13.65 |
Forward PE | 9.92 | 8.77 | 11.62 | 10.44 | 12.34 | 9.83 |
PS Ratio | 0.15 | 0.15 | 0.13 | 0.09 | 0.11 | 0.18 |
PB Ratio | 3.88 | 4.24 | 3.47 | 2.18 | 1.92 | 2.69 |
P/TBV Ratio | 4.19 | 4.64 | 3.89 | 2.57 | 1.97 | 2.72 |
P/OCF Ratio | 21.61 | - | - | 25.16 | 6.69 | - |
PEG Ratio | 0.30 | 0.19 | 0.26 | 0.33 | 0.35 | 0.41 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.47 | 0.46 | 0.42 | 0.45 | 0.50 | 0.50 |
EV/EBITDA Ratio | 10.27 | 9.54 | 9.69 | 11.96 | 18.48 | 13.97 |
EV/EBIT Ratio | 11.33 | 10.01 | 10.26 | 13.15 | 22.85 | 16.42 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 8.81 | 9.58 | 9.94 | 9.06 | 7.82 | 5.49 |
Debt / EBITDA Ratio | 7.32 | 6.91 | 8.08 | 9.83 | 14.82 | 9.47 |
Net Debt / Equity Ratio | 8.49 | 9.23 | 9.53 | 8.28 | 7.39 | 5.17 |
Net Debt / EBITDA Ratio | 7.36 | 6.92 | 8.10 | 9.48 | 15.62 | 9.57 |
Net Debt / FCF Ratio | -41.80 | -31.90 | -16.31 | -52.59 | -21.33 | -15.39 |
Asset Turnover | 2.27 | 2.36 | 2.37 | 2.16 | 1.84 | 2.12 |
Inventory Turnover | 7.77 | 9.47 | 10.53 | 10.82 | 8.30 | 9.02 |
Quick Ratio | 0.66 | 0.71 | 0.67 | 0.68 | 0.60 | 0.66 |
Current Ratio | 1.03 | 1.02 | 1.00 | 1.00 | 1.00 | 1.03 |
Return on Equity (ROE) | 38.93% | 39.54% | 35.32% | 15.75% | 12.60% | 22.31% |
Return on Assets (ROA) | 5.84% | 6.83% | 5.98% | 4.58% | 2.50% | 4.06% |
Return on Invested Capital (ROIC) | 10.27% | 12.55% | 11.32% | 7.63% | 4.81% | 5.87% |
Return on Capital Employed (ROCE) | 68.20% | 79.00% | 70.20% | 43.90% | 20.10% | 35.40% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 7.15% | 8.06% | 8.71% | 6.75% | 7.13% | 8.05% |
FCF Yield | -5.23% | -6.82% | -16.82% | -7.21% | -18.05% | -12.49% |
Dividend Yield | 1.32% | - | 2.34% | - | - | 2.69% |
Payout Ratio | 31.93% | 21.12% | 4.17% | 10.74% | 81.35% | 4.63% |
Buyback Yield / Dilution | - | - | - | - | 22.58% | -16.25% |
Total Shareholder Return | 1.32% | - | 2.34% | - | 22.58% | -13.56% |